Summit Therapeutics Stock Price, News & Analysis (NASDAQ:SMMT) $2.13 +0.10 (+4.93%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$1.93▼$2.1450-Day Range$1.67▼$2.1852-Week Range$0.66▼$5.78Volume1.70 million shsAverage Volume935,375 shsMarket Capitalization$1.49 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Summit Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish1.43% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.28Based on 2 Articles This WeekInsider TradingAcquiring Shares$5 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.21 out of 5 starsMedical Sector919th out of 952 stocksPharmaceutical Preparations Industry431st out of 445 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Summit Therapeutics. Previous Next 1.0 Short Interest Percentage of Shares Shorted1.43% of the outstanding shares of Summit Therapeutics have been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Summit Therapeutics has recently increased by 5.49%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSummit Therapeutics does not currently pay a dividend.Dividend GrowthSummit Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SMMT. Previous Next 2.9 News and Social Media Coverage News SentimentSummit Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Summit Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 10 people have searched for SMMT on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Summit Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,999,999.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders83.70% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.01% of the stock of Summit Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Summit Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Summit Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSummit Therapeutics has a P/B Ratio of 15.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Summit Therapeutics Stock (NASDAQ:SMMT)Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. The company's product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical stage for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. for research and develop Ivonescimab (AK112) and SMT112, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.Read More SMMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SMMT Stock News HeadlinesNovember 26, 2023 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $1.95November 7, 2023 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023December 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 7, 2023 | finance.yahoo.comSummit Therapeutics Inc (SMMT) Reports Q3 Financial Results and Operational ProgressNovember 2, 2023 | finance.yahoo.comIvonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023November 1, 2023 | bizjournals.comFormer Reata Pharmaceuticals CFO steps into new role with California biotech companyOctober 31, 2023 | finance.yahoo.comIvonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023October 26, 2023 | finance.yahoo.comSummit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023December 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 19, 2023 | finance.yahoo.comH. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical DevelopmentOctober 17, 2023 | finance.yahoo.comInsider Buying: COO Manmeet Soni Acquires 2,976,190 Shares of Summit Therapeutics IncSeptember 26, 2023 | msn.comSummit Therapeutics: Not For Retail InvestorsSeptember 25, 2023 | seekingalpha.comNavigating Summit Therapeutics' Bispecific Bet Amid Cash ConstraintsAugust 9, 2023 | finance.yahoo.comQ2 2023 Summit Therapeutics Inc Earnings CallAugust 9, 2023 | seekingalpha.comSummit Therapeutics, Inc. (SMMT) Q2 2023 Earnings Call TranscriptAugust 9, 2023 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023August 2, 2023 | finance.yahoo.comSummit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023July 11, 2023 | finance.yahoo.comSummit Therapeutics Insiders Up US$558m On US$517m InvestmentJune 4, 2023 | finance.yahoo.comPromising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023June 1, 2023 | finance.yahoo.comIvonescimab Updated Data to be Featured at ASCO 2023May 22, 2023 | finance.yahoo.com11 Stocks with Heavy Insider Buying in 2023May 18, 2023 | finance.yahoo.comAfter buying recently, Summit Therapeutics Inc. (NASDAQ:SMMT) insiders must be dismayed to see the company's market cap drop to US$1.2bMay 16, 2023 | finance.yahoo.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q1 2023 Earnings Call TranscriptMay 16, 2023 | finance.yahoo.comWhy Shares of Summit Therapeutics Slumped on TuesdayMay 12, 2023 | finance.yahoo.comQ1 2023 Summit Therapeutics Inc Earnings CallMay 11, 2023 | seekingalpha.comSummit Therapeutics, Inc. (SMMT) Q1 2023 Earnings Call TranscriptMay 11, 2023 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023See More Headlines Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SMMT CUSIPN/A CIK1599298 Webwww.summitplc.com Phone650-460-8308Fax44-12-3544-3999Employees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,780,000.00 Net MarginsN/A Pretax Margin-271,685.00% Return on Equity-64.01% Return on Assets-22.31% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80 Sales & Book Value Annual Sales$700,000.00 Price / Sales2,132.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book15.21Miscellaneous Outstanding Shares700,840,000Free Float114,237,000Market Cap$1.49 billion OptionableOptionable Beta-0.97 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Robert W. Duggan (Age 79)Co-CEO & Executive Chairman Dr. Mahkam Zanganeh D.D.S. (Age 53)M.B.A., Co-CEO, President & Director Comp: $934.85kMr. Ankur Dhingra (Age 47)Chief Financial Officer Comp: $668.39kMr. Manmeet Singh Soni (Age 45)COO & Director Dr. Urte Gayko Ph.D. (Age 52)Chief Regulatory, Quality & Pharmacovigilance Officer? Prof. Dame Kay Davies DBE (Age 72)FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor Ms. Shelley D. Spray (Age 58)Head of Corporate Education, Communications & Creative? Ms. Abby Guzman MurphyHead of Human ResourcesMs. Divya Chari (Age 55)Head of Global Clinical Operations Mr. Dave GancarzChief Business & Strategy Officer?More ExecutivesKey CompetitorsMerusNASDAQ:MRUSAbCellera BiologicsNASDAQ:ABCLRayzeBioNASDAQ:RYZBArvinasNASDAQ:ARVNDisc MedicineNASDAQ:IRONView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 11,696 shares on 11/24/2023Ownership: 0.009%Legal & General Group PlcBought 7,480 shares on 11/15/2023Ownership: 0.017%The Manufacturers Life Insurance Company Bought 21,149 shares on 11/15/2023Ownership: 0.010%Sectoral Asset Management Inc.Sold 30,000 shares on 11/15/2023Ownership: 0.003%AQR Capital Management LLCBought 19,225 shares on 11/15/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions SMMT Stock Analysis - Frequently Asked Questions How have SMMT shares performed in 2023? Summit Therapeutics' stock was trading at $4.25 at the start of the year. Since then, SMMT shares have decreased by 49.9% and is now trading at $2.13. View the best growth stocks for 2023 here. When is Summit Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our SMMT earnings forecast. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics Inc. (NASDAQ:SMMT) announced its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business earned $0.27 million during the quarter. What ETFs hold Summit Therapeutics' stock? ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP). When did Summit Therapeutics IPO? (SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager. Who are Summit Therapeutics' major shareholders? Summit Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.15%), Charles Schwab Investment Management Inc. (0.13%), Shell Asset Management Co. (0.05%), California State Teachers Retirement System (0.02%), Barclays PLC (0.02%) and Rhumbline Advisers (0.02%). Insiders that own company stock include Ankur Dhingra, Mahkam Zanganeh, Maky Zanganeh, Manmeet Singh Soni and Robert W Duggan. View institutional ownership trends. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SMMT) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.